세계의 연부 육종 시장 규모 조사 및 예측 : 치료법별, 투여 경로별, 최종 사용자별, 지역별 분석(2023-2030년)

Global Soft Tissue Sarcoma Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Soft tissue sarcoma is a type of cancer that originates in the soft tissues of the body, such as muscles, tendons, fat, nerves, blood vessels, and connective tissues. A lump or swelling in a body's soft tissue is an indication of soft tissue sarcoma. There are many different locations on the body where soft tissue sarcomas develop, which is identified through biopsy. The global market growth is driven by factors such as the rising adoption of novel therapies, growing focus on personalized medicine, escalating population, and increasing healthcare expenditure, coupled with favorable reimbursement policies.

In addition, the surge in the incidences of cancer is acting as a catalyzing factor for market growth across the globe. According to the World Health Organization, in 2020, it was estimated that around 19.3 million new cancer cases were recorded globally, which is projected to increase and likely to reach 30.3 million cases by the year 2040. Thus, these aforementioned factors are propelling the growth of the soft tissue sarcoma market during the estimated period. Moreover, the rising advancements in diagnostics and treatment options, as well as increasing investments in research and development is presenting various lucrative opportunities over the forecasting years. However, the high cost of treatments and the side effects of soft tissue sarcoma drugs are hampering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Soft Tissue Sarcoma Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the surging demand for targeted therapies, rising focus on personalized medicine, and the presence of well-established healthcare facilities. Whereas, Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the rising prevalence of soft tissue sarcoma, increasing healthcare expenditure, and growing investments in research and development.

Major market players included in this report are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Merck & Co., Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)

Recent Developments in the Market:

• In 2019, Pfizer announced that Vitrakvi (larotrectinib) had received European Commission approval for the treatment of advanced soft tissue sarcoma. Vitrakvi - a targeted medication is available to patients whose tumours have a particular genetic mutation.
• In 2019, Johnson & Johnson declared that the US Food and Drug Administration had authorized JNJ-4528 as a medication for the management of relapsed or refractory multiple myeloma. JNJ-4528 is a CAR-T cell therapy that is developed for use in the treatment of several malignancies, including some types of sarcomas.

Global Soft Tissue Sarcoma Market Report Scope:

• Historical Data: - 2020 - 2021
• Base Year for Estimation: - 2022
• Forecast period: - 2023-2030
• Report Coverage: - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: - Treatment, Route of Administration, End-users, Region
• Regional Scope: - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Treatment:

• Targeted Therapy
• Chemotherapy
• Anti-Angiogenesis Drugs
• Radiation Therapy

By Route of Administration:

• Oral
• Parenteral
• Others

By End-users:

• Hospitals
• Homecare
• Speciality Centres
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Soft Tissue Sarcoma Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Soft Tissue Sarcoma Market, by Treatment, 2020-2030 (USD Billion)
  • 1.2.3. Soft Tissue Sarcoma Market, by Route of Administration, 2020-2030 (USD Billion)
  • 1.2.4. Soft Tissue Sarcoma Market, by End-users, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Soft Tissue Sarcoma Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Soft Tissue Sarcoma Market Dynamics

• 3.1. Soft Tissue Sarcoma Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Rising adoption of novel therapies
    • 3.1.1.2. Surge in the incidences of cancer
  • 3.1.2. Market Challenges
    • 3.1.2.1. High cost of treatments
    • 3.1.2.2. Side effects of soft tissue sarcoma drugs
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Rising advancements in diagnostics and treatment options
    • 3.1.3.2. Increasing investments in research and development

Chapter 4. Global Soft Tissue Sarcoma Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Soft Tissue Sarcoma Market, by Treatment

• 5.1. Market Snapshot
• 5.2. Global Soft Tissue Sarcoma Market by Treatment, Performance - Potential Analysis
• 5.3. Global Soft Tissue Sarcoma Market Estimates & Forecasts by Treatment 2020-2030 (USD Billion)
• 5.4. Soft Tissue Sarcoma Market, Sub Segment Analysis
  • 5.4.1. Targeted Therapy
  • 5.4.2. Chemotherapy
  • 5.4.3. Anti-Angiogenesis Drugs
  • 5.4.4. Radiation Therapy

Chapter 6. Global Soft Tissue Sarcoma Market, by Route of Administration

• 6.1. Market Snapshot
• 6.2. Global Soft Tissue Sarcoma Market by Route of Administration, Performance - Potential Analysis
• 6.3. Global Soft Tissue Sarcoma Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
• 6.4. Soft Tissue Sarcoma Market, Sub Segment Analysis
  • 6.4.1. Oral
  • 6.4.2. Parenteral
  • 6.4.3. Others

Chapter 7. Global Soft Tissue Sarcoma Market, by End-users

• 7.1. Market Snapshot
• 7.2. Global Soft Tissue Sarcoma Market by End-users, Performance - Potential Analysis
• 7.3. Global Soft Tissue Sarcoma Market Estimates & Forecasts by End-users 2020-2030 (USD Billion)
• 7.4. Soft Tissue Sarcoma Market, Sub Segment Analysis
  • 7.4.1. Hospitals
  • 7.4.2. Homecare
  • 7.4.3. Speciality Centres
  • 7.4.4. Others

Chapter 8. Global Soft Tissue Sarcoma Market, Regional Analysis

• 8.1. Top Leading Countries
• 8.2. Top Emerging Countries
• 8.3. Soft Tissue Sarcoma Market, Regional Market Snapshot
• 8.4. North America Soft Tissue Sarcoma Market
  • 8.4.1. U.S. Soft Tissue Sarcoma Market
    • 8.4.1.1. Treatment breakdown estimates & forecasts, 2020-2030
    • 8.4.1.2. Route of Administration breakdown estimates & forecasts, 2020-2030
    • 8.4.1.3. End-users breakdown estimates & forecasts, 2020-2030
  • 8.4.2. Canada Soft Tissue Sarcoma Market
• 8.5. Europe Soft Tissue Sarcoma Market Snapshot
  • 8.5.1. U.K. Soft Tissue Sarcoma Market
  • 8.5.2. Germany Soft Tissue Sarcoma Market
  • 8.5.3. France Soft Tissue Sarcoma Market
  • 8.5.4. Spain Soft Tissue Sarcoma Market
  • 8.5.5. Italy Soft Tissue Sarcoma Market
  • 8.5.6. Rest of Europe Soft Tissue Sarcoma Market
• 8.6. Asia-Pacific Soft Tissue Sarcoma Market Snapshot
  • 8.6.1. China Soft Tissue Sarcoma Market
  • 8.6.2. India Soft Tissue Sarcoma Market
  • 8.6.3. Japan Soft Tissue Sarcoma Market
  • 8.6.4. Australia Soft Tissue Sarcoma Market
  • 8.6.5. South Korea Soft Tissue Sarcoma Market
  • 8.6.6. Rest of Asia Pacific Soft Tissue Sarcoma Market
• 8.7. Latin America Soft Tissue Sarcoma Market Snapshot
  • 8.7.1. Brazil Soft Tissue Sarcoma Market
  • 8.7.2. Mexico Soft Tissue Sarcoma Market
• 8.8. Middle East & Africa Soft Tissue Sarcoma Market
  • 8.8.1. Saudi Arabia Soft Tissue Sarcoma Market
  • 8.8.2. South Africa Soft Tissue Sarcoma Market
  • 8.8.3. Rest of Middle East & Africa Soft Tissue Sarcoma Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. Company 1
  • 9.1.2. Company 2
  • 9.1.3. Company 3
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. F. Hoffmann-La Roche Ltd. (Switzerland)
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Recent Developments
  • 9.3.2. Mylan N.V. (U.S.)
  • 9.3.3. Teva Pharmaceutical Industries Ltd. (Israel)
  • 9.3.4. Sanofi (France)
  • 9.3.5. Pfizer Inc. (U.S.)
  • 9.3.6. GSK plc (U.K.)
  • 9.3.7. Novartis AG (Switzerland)
  • 9.3.8. Bayer AG (Germany)
  • 9.3.9. Merck & Co., Inc. (U.S.)
  • 9.3.10. Sun Pharmaceutical Industries Ltd. (India)

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes
• 10.3. Research Assumption